Product Description
ASP2205 showed potent and selective agonistic activity for the human 5-HT2Creceptor, with an EC50of 0.85 nM in the intracellular Ca2+mobilization assay.
Mechanisms of Action: 5-HT2C Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Astellas Pharma
Company Location: NEW YORK NY 10005
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| 2205-CL-0001 | P1 |
Terminated |
Healthy Volunteers |
2015-10-01 |
2019-03-20 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|